Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch, analyses DelveInsight

Eczema Major players in the pipeline include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
DelveInsight's "Eczema Pipeline Insights 2026" report delivers an extensive analysis of more than 100 companies and 100+ investigational therapies within the eczema pipeline landscape. The study evaluates drug profiles across both clinical and preclinical stages. It further categorizes pipeline candidates based on product type, development phase, route of administration, and molecular class. The report also outlines inactive and discontinued programs within this therapeutic space.

Explore the newest investigational drugs and therapeutic strategies in the eczema pipeline with DelveInsight's in-depth report - Eczema Clinical Trial Outlook [https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Highlights from the Eczema Pipeline Report

* In December 2025, Pfizer initiated a clinical study to evaluate whether abrocitinib improves eczema symptoms and maintains safety in children aged 6 and above.
* In December 2025, Inmagene LLC conducted a Phase IIb, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial assessing the efficacy and safety of various dose regimens of IMG-007 in adults with moderate-to-severe active atopic dermatitis for up to 52 weeks.
* In December 2025, Evommune Inc. announced the initiation of a Phase IIa study evaluating the safety and effectiveness of EVO301 in adult atopic dermatitis patients.
* In December 2025, Arcutis Biotherapeutics Inc. reported a study designed to assess the safety and tolerability of ARQ-151 cream 0.05%, administered once daily for four weeks in infants diagnosed with atopic dermatitis (eczema).
* DelveInsight's eczema pipeline analysis illustrates a dynamic and competitive landscape, with over 100 active companies collectively advancing 100+ therapeutic candidates.
* Major players in the eczema pipeline include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
* Noteworthy pipeline therapies include alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.

Stay informed with the latest developments in eczema research, clinical trials, and innovative therapies through DelveInsight's comprehensive pipeline analysis - https://www.delveinsight.com/report-store/eczema-pipeline-insight [https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Eczema Pipeline Report Overview

The eczema pipeline report offers a detailed disease overview, pipeline landscape evaluation, and therapeutic assessment of leading investigational drugs. It also identifies existing gaps and unmet medical needs within the eczema treatment paradigm.

Eczema Disease Overview

Eczema, commonly referred to as atopic dermatitis, represents the most prevalent form of dermatitis. Its pathogenesis is believed to involve both genetic predisposition and environmental triggers. Although it frequently manifests in children, eczema can also affect adults. Patients typically experience dry, itchy, and infection-prone skin. The condition is often described as the "itch that rashes," as persistent scratching of dry skin results in inflammatory eruptions.

Primary treatment strategies emphasize consistent skin hydration, followed by topical corticosteroids during flare-ups. The lifetime prevalence of atopic dermatitis is estimated at approximately 15-30% in children and 2-10% in adults.

Emerging Drugs in the Eczema Pipeline

Amlitelimab: Kymab

Amlitelimab (SAR445229), formerly known as KY1005, is a human monoclonal antibody targeting OX40L, an important immune system regulator. Developed by Kymab, the therapy aims to rebalance immune responses by blocking pro-inflammatory effector T-cell activation while promoting regulatory T-cell expansion, without causing broad immune suppression.

In Phase I studies involving healthy volunteers, Amlitelimab successfully reduced T cell-mediated skin inflammation and demonstrated favorable tolerability. The drug is currently undergoing Phase II clinical evaluation for eczema and holds potential across various autoimmune and inflammatory disorders.

BX005: BiomX

BX005 is a topical bacteriophage cocktail developed by BiomX, designed to target Staphylococcus aureus , a bacterium strongly associated with atopic dermatitis pathogenesis. Preclinical in vitro studies demonstrated activity against over 90% of S. aureus strains isolated from US and European patients, including antibiotic-resistant variants. The therapy is presently in Phase I/II development for atopic dermatitis.

LP 0145: LEO Pharma

LP 0145, an anti-inflammatory monoclonal antibody from LEO Pharma, is currently in Phase II clinical development for eczema treatment.

Key Insights from the Eczema Pipeline Report

* Detailed company-level analysis of therapeutic candidates under development for eczema.
* Categorization of pipeline assets into early-stage, mid-stage, and late-stage development.
* Overview of both active and inactive (dormant or discontinued) projects.
* Segmentation by development phase, route of administration, molecular target, monotherapy or combination strategy, mechanism of action, and molecular type.
* Comprehensive review of collaborations, licensing agreements, funding activities, and strategic partnerships shaping the future eczema market.

Explore groundbreaking therapies and clinical trials in the Eczema Pipeline. Access DelveInsight's detailed report now! @ https://www.delveinsight.com/sample-request/eczema-pipeline-insight

Eczema Companies

Key organizations driving innovation in eczema therapeutics include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

Route of Administration (ROA) Segmentation

Pipeline products are classified under multiple administration routes, including:

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Molecule Type Classification

Eczema pipeline therapies are grouped based on molecular structure, including:

* Oligonucleotides
* Peptides
* Small molecules

Unveil the future of Eczema Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ https://www.delveinsight.com/sample-request/eczema-pipeline-insight [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Eczema Pipeline Report

* Coverage- Global
* Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
* Eczema Pipeline Therapies- alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.
* Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Eczema Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ https://www.delveinsight.com/sample-request/eczema-pipeline-insight

Table of Contents

* Introduction
* Executive Summary
* Eczema Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* DelveInsight's Analytical Perspective
* Late-Stage Products (Phase III)
* Drug Profiles (Detailed)
* Mid-Stage Products (Phase II)
* Amlitelimab: Kymab
* Early-Stage Products (Phase I)
* Preclinical & Discovery Programs
* Inactive Products
* Key Companies
* Key Products
* Unmet Needs
* Market Drivers and Barriers
* Future Outlook and Conclusion
* Analyst Perspectives
* Appendix

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eczema-pipeline-2026-outlook-100-clinical-assets-and-3-key-latestage-candidates-to-watch-analyses-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.